OPEN-LABEL COMPARISON OF OLANZAPINE LONG-ACTING INJECTION AND ORAL OLANZAPINE: A 2-YEAR, RANDOMIZED STUDY IN OUTPATIENTS WITH SCHIZOPHRENIA

被引：0
作者：
Detke, Holland C. [1 ]
Weiden, Peter J. [2 ]
Llorca, P. M. [3 ]
Choukour, M. [4 ]
Watson, Susan B. [1 ]
Brunner, E. [1 ]
Ascher-Svanum, H. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
[3] Ctr Hosp Univ, Psychiat Serv, Clermont Ferrand, France
[4] i3 Statprobe, Med Writing & Sci Commun, San Diego, CA USA
来源：
SCHIZOPHRENIA BULLETIN | 2011年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：300 / 300
页数：1
相关论文
共 50 条
  • [31] Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison
    Dilla, Tatiana
    Moeller, Joergen
    O'Donohoe, Paul
    Alvarez, Maria
    Sacristan, Jose A.
    Happich, Michael
    Tockhorn, Antje
    BMC PSYCHIATRY, 2014, 14
  • [32] EFFECTIVENESS OF 300MG/4WEEKS OLANZAPINE LONG-ACTING INJECTION FROM DATA MINING OF AN OPEN-LABEL EXTENSION STUDY
    Dyachkova, Yulia
    Barraco, Alessandra
    Toth, Agoston
    Anand, Hemant
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 264 - 265
  • [33] Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
    Di Lorenzo, Rosaria
    Brogli, Alice
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 573 - 581
  • [34] Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in 1 year randomized, open-label trial
    Ciudad, Antonio
    Olivares, Jose M.
    Bousono, Manuel
    Gomez, Juan C.
    Alvarez, Enrigue
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (08) : 1515 - 1522
  • [35] COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY
    Carroll, S. M.
    Jemiai, N.
    Suter, B.
    O'Donohoe, P.
    Skjoldborg, U.
    Moller, J.
    Kleivenes, O. K.
    Novick, D.
    VALUE IN HEALTH, 2009, 12 (07) : A358 - A358
  • [36] Olanzapine in treatment-refractory schizophrenia: Results of an open-label study
    Martin, J
    Gomez, JC
    GarciaBernardo, E
    Cuesta, M
    Alvarez, E
    Gurpegui, M
    JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 (11) : 479 - 483
  • [37] Comparison of outcomes in patients with early versus later phase schizophrenia treated with olanzapine long-acting injection
    Detke, H.
    Correll, C.
    Liu, C.
    Landry, J.
    Feldman, P.
    McDonnell, D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 114 - 114
  • [38] Childhood-onset schizophrenia: An open-label study of olanzapine in adolescents
    Kumra, S
    Jacobsen, LK
    Lenane, M
    Karp, BI
    Frazier, JA
    Smith, AK
    Bedwell, J
    Lee, P
    Malanga, CJ
    Hamburger, S
    Rapoport, JI
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1998, 37 (04) : 377 - 385
  • [39] Childhood-onset schizophrenia: An open-label study of olanzapine in adolescents
    Kumra, S
    Jacobsen, LK
    Rapoport, JL
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 149 - 149
  • [40] "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels
    Mauri, Massimo C.
    Maffini, Michele
    Di Pace, Chiara
    Reggiori, Alessandra
    Paletta, Silvia
    Moliterno, Donatella
    Rovera, Chiara
    Altamura, Carlo A.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2015, 19 (02) : 99 - 105
12345